Journal article

Identification of a novel percent mammographic density locus at 12q24

Kristen N Stevens, Sara Lindstrom, Christopher G Scott, Deborah Thompson, Thomas A Sellers, Xianshu Wang, Alice Wang, Elizabeth Atkinson, David N Rider, Jeanette E Eckel-Passow, Jajini S Varghese, Tina Audley, Judith Brown, Jean Leyland, Robert N Luben, Ruth ML Warren, Ruth JF Loos, Nicholas J Wareham, Jingmei Li, Per Hall Show all

Human Molecular Genetics | OXFORD UNIV PRESS | Published : 2012

Grants

Awarded by National Institutes of Health


Awarded by National Heart, Lung and Blood Institute


Awarded by National Human Genome Research Institute


Awarded by National Cancer Institute


Awarded by Centers for Disease Control


Awarded by Public Health Service from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services and Breast Cancer Research Fund


Awarded by Cancer Research UK


Awarded by Mayo Clinic Breast Cancer SPORE


Awarded by Mayo Clinic Pharmacogenomics Research Network Center



Awarded by Medical Research Council


Funding Acknowledgements

This work and the MBCFS study were supported by National Institutes of Health grant R01 CA128931. The Mayo VTE was supported by National Heart, Lung and Blood Institute grant HL83131; National Human Genome Research Institute grant HG04735; National Cancer Institute grant CA92153; and Centers for Disease Control grant DD000235. MAY was supported by National Institutes of Health grants R01 CA122443, R01 CA114343 and P50 CA136393. The EPIC-Norfolk study was funded by research programme grant funding from Cancer Research UK and the Medical Research Council with additional support from the Stroke Association, British Heart Foundation, Department of Health, Research into Ageing and Academy of Medical Sciences. NHS was supported by Public Health Service Grants CA131332, CA087969, CA049449, CA089393 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services and Breast Cancer Research Fund. The NHS Phase I breast cancer cases and controls were genotyped with support from the National Cancer Institute's Cancer Markers of Susceptibility (CGEMS) initiative. SASBAC was supported by National Institutes of Health grant R01 CA58427; Marit and Hans Rausing's Initiative Against Breast Cancer; the W81XWH-05-1-0314 Innovator Award; US Department of Defense Breast Cancer Research Program; Office of the Congressionally Directed Medical Research Programs; and the Agency for Science, Technology and Research (A*STAR). Genotyping in the TORONTO/MELBOURNE subjects was supported by the Campbell Family Institute for Breast Cancer Research. Support was also provided by the Ontario Ministry of Health and Long Term Care. The SIBS study was supported by Cancer Research UK programme grant C1287/A10118 and Cancer Research UK project grants C1287 and C8459. D. F. E. is a Principal Research Fellow of Cancer Research UK. MCBCS was supported by Mayo Clinic Breast Cancer SPORE P50 CA116201 and National Institutes of Health grant R01 CA122340.MAYO PGRN was supported by Mayo Clinic Pharmacogenomics Research Network Center U19 GM61388 and the Mayo Clinic Breast Cancer SPORE P50 CA116201.